Synthomer Utdelningar och återköp
Utdelning kriterier kontrolleras 0/6
Synthomer betalar för närvarande ingen utdelning.
Viktig information
0%
Avkastning på utdelning
0.06%
Återköpsavkastning
| Total avkastning till aktieägarna | 0.06% |
| Framtida utdelningsavkastning | 0% |
| Utdelningstillväxt | n/a |
| Nästa utbetalningsdag för utdelning | n/a |
| Ex utdelningsdag | n/a |
| Utdelning per aktie | n/a |
| Utdelningsandel | 0% |
Senaste utdelnings- och återköpsuppdateringar
Inga uppdateringar
Recent updates
Uppdatering av berättelse • Aug 17
SYNT: Higher Profitability Assumptions And Execution On Plans Will Support Future Upside
Analysts have trimmed their fair value estimate for Synthomer from £1.47 to £1.28, even as recent price target increases on the stock point to updated views on revenue growth, profitability and future P/E assumptions. Analyst Commentary Recent research on Synthomer gives investors a mixed message.Analysartikel • Aug 08
Analysts Have Lowered Expectations For Synthomer plc (LON:SYNT) After Its Latest Results
Shareholders will be ecstatic, with their stake up 39% over the past week following Synthomer plc 's ( LON:SYNT...
Uppdatering av berättelse • Aug 03
SYNT: Higher Fair Value And Execution Risks Will Shape Future Earnings
Analysts have raised their price target on Synthomer to £0.92 from £0.62, citing updated assumptions for fair value, revenue growth, profit margins and future P/E as key factors supporting the new level. Analyst Commentary Recent research updates on Synthomer suggest that, while targets have been adjusted, many analysts remain cautious about the stock.
Uppdatering av berättelse • Jul 20
SYNT: Recent Price Objective Revisions Will Shape A More Constructive Outlook
The Analyst Price Target on Synthomer has been adjusted from £3.48 to £2.00 per share, reflecting analysts' updated assumptions on fair value, discount rate, and earnings profile in light of recent price target increases from £0.62 to £0.92 and an additional £0.40 uplift cited in Street research. Analyst Commentary Recent Street research on Synthomer points to a more constructive tone, with bullish analysts revisiting their fair value assumptions and revising price targets.Uppdatering av berättelse • Jul 06
SYNT: Cost Actions And Execution On Plans Will Support Future Upside
Analysts have lifted their fair value estimate for Synthomer from £1.27 to £1.47, reflecting higher price targets from the Street and updated assumptions around revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street commentary on Synthomer points to a more constructive stance on the stock, with price targets moving higher and ratings generally sitting in the neutral range.Uppdatering av berättelse • Jun 22
SYNT: Leadership Change And Higher Risk Profile Will Pressure Future Earnings
Analysts have lifted their price target on Synthomer by £0.40, citing updated assumptions around discount rates, revenue growth and future P/E that they view as better aligned with the company’s current risk and earnings profile. What’s in the News for Synthomer Synthomer announced that Chief Financial Officer Lily Liu plans to step down to become Executive Vice President and Chief Financial Officer at Umicore SA.Uppdatering av berättelse • Jun 06
SYNT: Leadership Transition Will Intensify Concerns Over Future Margin Stability
Analysts have nudged Synthomer's fair value higher, lifting the implied price target from £0.59 to £0.62. This reflects refreshed assumptions on revenue growth, discount rate and future P/E.Uppdatering av berättelse • May 04
SYNT: Bio-Based Shift Will Face Margin And Leadership Risks Ahead
Analysts have kept their Synthomer fair value target steady at £0.59. This reflects a view that a shift from a previous revenue contraction of 32.37% to expected growth of 2.61%, together with a slightly lower projected profit margin of 9.99%, leaves the overall valuation framework broadly unchanged.Uppdatering av berättelse • Apr 20
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Stability
Analysts have slightly reduced their price expectations for Synthomer, reflecting updated assumptions for a less pronounced revenue decline, a small reduction in forecast profit margins, and a modest adjustment to future P/E. Taken together, these changes leave their fair value estimate unchanged at £0.59 per share.Uppdatering av berättelse • Apr 06
SYNT: Cost Cuts And Bio Based Shift Will Support Future Upside
Analysts have nudged their price target on Synthomer slightly, reflecting modest tweaks to assumptions around discount rate, profit margin and future P/E, while keeping the underlying fair value estimate broadly unchanged at £1.27. What's in the News Godavari Biorefineries Limited entered a partnership with Synthomer to develop bio-based alternatives to existing fossil-based monomers, targeting growing customer demand for lower carbon and more sustainable materials (Key Developments).Uppdatering av berättelse • Mar 23
SYNT: Cost Actions And Bio-Based Partnership Will Support Future Margin Resilience
Analysts have adjusted their Synthomer price targets slightly to reflect updated views on revenue contraction, slightly higher profit margins, and a modestly lower future P/E, resulting in a revised fair value estimate of £0.59 per share. What's in the News Synthomer entered a partnership with Godavari Biorefineries Limited to develop bio-based alternatives to existing fossil-based monomers.Uppdatering av berättelse • Mar 09
SYNT: Cost Actions And Bio Based Shift Will Support Earnings Recovery
Analysts have trimmed their price target on Synthomer from £1.34 to about £1.27, citing updated assumptions on revenue growth, profit margins and future P/E multiples as they reassess the balance of risk and reward. What's in the News Godavari Biorefineries Limited partnered with Synthomer to develop bio-based alternatives to existing fossil-based monomers, including commercialisation of bio-based butyl acrylate using bio-based butanol from GBL, aimed at supporting customer demand for lower carbon materials (Key Developments).Uppdatering av berättelse • Feb 22
SYNT: Cost Actions And Bio-Based Shift Will Support Future Margin Resilience
Analysts have nudged their price target on Synthomer higher to £0.59. This reflects updated assumptions around slightly less severe revenue contraction and broadly unchanged profit margins and P/E expectations.Uppdatering av berättelse • Feb 08
SYNT: Cost Actions And Margin Resilience Will Support A Stable Fair Value View
Analysts have nudged their fair value estimate for Synthomer to £0.59 from £0.55, citing revised assumptions around revenue growth, profit margins and future P/E as the key drivers of the updated price target. What's in the News Synthomer issued earnings guidance for the twelve months to 31 December 2025, with expected 2025 revenue of around £1.74b compared with £1.93b for 2024, described as in line with market expectations (Key Developments).Uppdatering av berättelse • Jan 24
SYNT: Earnings Prospects Will Stabilise As Fair Value View Remains Intact
Analysts have adjusted their price targets on Synthomer, reflecting revised assumptions around revenue growth, profit margins and future P/E multiples. Together, these changes point to a recalibrated view of the company’s earnings potential within an unchanged fair value estimate of £0.55 per share.Uppdatering av berättelse • Jan 10
SYNT: Self Help And 2026 Outlook Will Support Earnings Recovery
Analysts have trimmed their price expectations for Synthomer, with a lower fair value estimate and a reduced Street target to £1.02 from £1.12. This reflects updated views on revenue growth and earnings multiples while maintaining a broadly neutral stance on the shares.Uppdatering av berättelse • Dec 24
SYNT Will Face Mounting Pressure As Earnings Recovery Outlook Deteriorates
The analyst price target for Synthomer has been reduced to £1.02 per share from £1.12, as analysts factor in slower revenue growth assumptions, despite slightly higher profit margin expectations and a marginally increased discount rate. Analyst Commentary Recent research updates highlight a cautious stance from bearish analysts, who have progressively lowered their price targets on Synthomer as they reassess the company’s growth trajectory and risk profile.Uppdatering av berättelse • Dec 10
SYNT: Self-Help Actions Will Drive Earnings Recovery Despite Neutral Market Sentiment
Analysts have trimmed their price target on Synthomer slightly. This reflects a modest recalibration in fair value to approximately £1.34 per share following a series of recent target cuts that have reset expectations for the stock.Uppdatering av berättelse • Nov 26
SYNT: Full-Year Self-Help Actions Will Drive Earnings Recovery Momentum
Analysts have revised their price target for Synthomer downward from GBp 112 to GBp 102. This change is attributed to adjustments to future valuation metrics and an updated earnings outlook.Uppdatering av berättelse • Nov 07
SYNT: Future Gains Are Expected As End Markets Gradually Stabilize
Synthomer's analyst price target has been reduced from 112 GBp to 102 GBp. Analysts cite persistent end-market challenges and limited near-term prospects for earnings recovery as key factors behind the downward revision. Analyst Commentary Recent analyst coverage reflects a spectrum of perspectives regarding Synthomer's outlook, shaped by evolving market dynamics and the company's updated financial guidance.Uppdatering av berättelse • Oct 24
Future Earnings And Recovery Prospects Will Remain Under Pressure Amid Market Challenges
Synthomer's fair value estimate has been revised downward from £1.54 to £1.38 per share. Analysts cite ongoing challenges in end markets and modest growth prospects following the company's recent interim results.Analysartikel • Aug 09
UK£1.57: That's What Analysts Think Synthomer plc (LON:SYNT) Is Worth After Its Latest Results
There's been a major selloff in Synthomer plc ( LON:SYNT ) shares in the week since it released its half-year report...Uppdatering av berättelse • Aug 07
Sustainable Specialty Polymers Will Unlock New Global Opportunities
Despite a notable upgrade in revenue growth forecasts and a reduction in the forward P/E, Synthomer's consensus analyst price target has been revised down from £1.71 to £1.57. Valuation Changes Summary of Valuation Changes for Synthomer The Consensus Analyst Price Target has fallen from £1.71 to £1.57.
Ny berättelse • Mar 31
Chemical Realignment And Adhesives Expansion Will Build A Resilient Future
Shift to high-margin specialty chemicals and divestment of non-core operations are expected to enhance profitability.Analysartikel • Jan 08
Investors Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues
Synthomer plc's ( LON:SYNT ) price-to-sales (or "P/S") ratio of 0.1x might make it look like a buy right now compared...Analysartikel • Oct 05
Synthomer plc (LON:SYNT) Screens Well But There Might Be A Catch
You may think that with a price-to-sales (or "P/S") ratio of 0.2x Synthomer plc ( LON:SYNT ) is a stock worth checking...Analysartikel • Aug 03
Calculating The Intrinsic Value Of Synthomer plc (LON:SYNT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£2.63 With UK£2.46 share...Analysartikel • Jun 18
Synthomer (LON:SYNT) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • May 25
Investors Still Aren't Entirely Convinced By Synthomer plc's (LON:SYNT) Revenues Despite 27% Price Jump
Synthomer plc ( LON:SYNT ) shares have continued their recent momentum with a 27% gain in the last month alone. Still...Analysartikel • Apr 20
Is Synthomer plc (LON:SYNT) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, Synthomer fair value estimate is UK£1.84 Current share price...Analysartikel • Mar 14
Even With A 45% Surge, Cautious Investors Are Not Rewarding Synthomer plc's (LON:SYNT) Performance Completely
Synthomer plc ( LON:SYNT ) shareholders would be excited to see that the share price has had a great month, posting a...Analysartikel • Feb 08
Should You Think About Buying Synthomer plc (LON:SYNT) Now?
While Synthomer plc ( LON:SYNT ) might not have the largest market cap around , it saw a double-digit share price rise...Stabilitet och tillväxt i betalningar
Hämta utdelningsdata
Stabil utdelning: Otillräcklig data för att avgöra om SYNT s utdelningar per aktie har varit stabila tidigare.
Växande utdelning: Otillräcklig data för att avgöra om SYNT s utdelningsbetalningar har ökat.
Utdelningsavkastning jämfört med marknaden
| Synthomer Utdelningsavkastning jämfört med marknaden |
|---|
| Segment | Utdelningsavkastning |
|---|---|
| Företag (SYNT) | 0% |
| Marknadens lägsta 25% (GB) | 2.1% |
| Marknad Topp 25% (GB) | 5.6% |
| Genomsnitt för branschen (Chemicals) | 3.8% |
| Prognosanalytiker (SYNT) (upp till 3 år) | 0% |
Anmärkningsvärd utdelning: Det går inte att utvärdera SYNT s utdelningsavkastning mot de lägsta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Hög utdelning: Det går inte att utvärdera SYNT s utdelningsavkastning mot de översta 25 % av utdelningsbetalarna, eftersom företaget inte har rapporterat några senaste utbetalningar.
Vinstutdelning till aktieägarna
Resultattäckning: SYNT betalar ingen anmärkningsvärd utdelning för UK marknaden.
Kontantutbetalning till aktieägarna
Kassaflödestäckning: Det går inte att beräkna hållbarheten för utdelningar eftersom SYNT inte har rapporterat några utbetalningar.
Upptäck bolag med stark utdelning
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/16 11:50 |
| Aktiekurs vid dagens slut | 2026/09/16 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Synthomer plc bevakas av 14 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Sebastian Bray | Berenberg |
| Rikin Patel | BNP Paribas |
| Kevin Fogarty | Deutsche Bank |